Somatostatin modulates important physiologic functions of the kidney,
including mesangial cell contraction, glomerular prostaglandin synthes
is, and phosphate, water and sodium excretion. In diabetic nephropathy
, somatostatin inhibits renal hypertrophy. High affinity somatostatin
receptors are expressed in the kidney. Circulating somatostatin concen
trations, however, are generally well below the affinity constants of
known somatostatin receptors. Thus, we hypothesized that somatostatin
is produced in the kidney and released locally to act in an autocrine/
paracrine manner. Using reverse transcriptase and polymerase chain rea
ction (RT-PCR) analysis, we found that fresh human renal cortex and cu
ltured human mesangial cells express somatostatin mRNA. Restriction en
zyme and Southern blot analysis confirmed that RT-PCR cDNA products we
re derived from somatostatin mRNA. Radioimmunoassay of mesangial cell
culture supernatants demonstrated SS-immunoreactive peptide (87+/-30 p
g/ml compared to 19+/-9 pg/ml in medium not exposed to cells; P < 0.05
). In contrast, renal cells did not transcribe detectable levels of va
soactive intestinal peptide (VIP) or neuropeptide Y (NPY) mRNA, nor di
d they synthesize measurable peptide. Our results demonstrate that ren
al cells produce somatostatin and suggest that kidney-derived somatost
atin may regulate renal function in an autocrine/paracrine manner. Cha
racterization of this pathway may lead to novel methods to alter the c
ourse of diabetic nephropathy and other renal diseases. (C) 1997 Elsev
ier Science B.V.